Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

CT-related radiation blamed for up to 2% of US cancers

December 1, 2007
By James Brice
James Brice
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

A New England Journal of Medicine review article is highlighting the cancer risks of computed tomography at the same time that hundreds of scientific presentations and new product announcements at the 2007 RSNA meeting are fueling the continued growth of multislice CT.

A New England Journal of Medicine review article is highlighting the cancer risks of computed tomography at the same time that hundreds of scientific presentations and new product announcements at the 2007 RSNA meeting are fueling the continued growth of multislice CT.

David J. Brenner, PhD, DSc, and Eric J. Hall, DPhil, DSc, both associated with the Center for Radiological Research at Columbia University, conclude from an examination of CT physics and often-quoted historical data from survivors of the Hiroshima and Nagasaki atomic bomb blasts that the growth of medical CT utilization may be responsible for 1.5% to 2% of US cancer cases.

They estimate that perhaps 20 million adults and more than 1 million children per year in the United States are irradiated unnecessarily from medical CT (N Engl J Med 357:2277-2284, 2007).

The rapid growth of CT utilization—from 3 million procedures in 1980 to 62 million scans per year in the mid-2000s—form that basis for Brenner and Hall's concerns. They say the risks for any one person are not large, but the increasing exposure to radiation may be a future public health issue.

Their analysis pegs that growth to the proliferation of multislice CT technology and screening applications for adults and children. They expressed concern about the growing popularity of CT for presurgical diagnosis of appendicitis for children, for example, because diagnostic ultrasound, a modality that involves no ionizing radiation, is probably equally effective for the same procedure.

They cite estimates indicating that 6% to 11% of CT studies are performed on children. A chart in the review indicates that a neonatal abdominal CT exposes a newborn infant to 20 mSv of radiation.

Screening is also an important motivation for increased CT use for asymptomatic adults, according to the authors. They predict that future utilization growth will arise from virtual CT colonoscopy, CT lung cancer screening, cardiac screening, and whole-body screening.

Citing atomic bomb survivor data, Brenner and Hall say that a substantial proportion of the 25,000 survivors received less than 50 mSv exposure, the equivalent of about three cardiac CT scans. A significant increase in the overall risk of cancer was recorded for the subgroup of atomic bomb survivors who received low doses of radiation in the 5 to 50 mSv range, they wrote.

"There is direct evidence from epidemiologic studies that the organ doses corresponding to a common CT study (two or three scans) result in an increased risk of cancer," they wrote. "The evidence is reasonably convincing for adults and very convincing for children."

Part of the issue, they wrote, "is that physicians often view CT studies in the same light as other radiologic procedures, even though radiation doses are typically much higher with CT than with other radiologic procedures."

In a recent survey of radiologist and ER physicians, they said, about 75% of the group significantly underestimated the radiation dose from a CT scan. Further, 53% of the radiologists and 91% of the ER physicians did not believe that CT scans increase the lifetime cancer risk.

In light of these findings, the authors said they welcomed the recent distribution among the medical community of the pamphlet "Radiation Risks and Pediatric Computed Tomography (CT): A Guide for Health Care Providers." The pamphlet can be found on NCI's website: http://www.nci.nih.gov/cancertopics/causes/radiation-risks-pediatric-CT.

The authors recommend better equipment and techniques to lower radiation exposure and the alternative use of MRI and ultrasound, especially for infants and children. They urge physicians to avoid inappropriate CT utilization.

Skepticism from ACR

The American College of Radiology expressed skepticism about the article. In a release, ACR noted that no published research exists to support Brenner and Hall's claim that radiation from CT may cause up to 2% of all cancers in the United States. ACR challenged the correlation between atomic bomb blast data and controlled exposure to radiation involved with CT scanning.

Arl Van Moore, Jr., MD, chair of the ACR board of chancellors, worried that patients may mistakenly avoid what the ACR characterized as "life-saving medical imaging care," because of the article.

"They may be terribly confused and unduly distressed by some of the statements in this study," he said.

Michael Brant-Zawadzki, MD, of RSNA's public information advisor's network, said many radiologists agree that inappropriate CT scans are done because of medico-legal concerns and exploitation by profit-driven referring physicians and commercial imaging providers.

The theoretical risk of carcinogenesis from radiation discussed by Brenner and Hall has been debated for decades. Experts disagree over whether carcinogenesis occurs at the low dose levels generated by CT scanners, Dr. Brant-Zawadzki said.

CT has become the diagnostic workhorse in hospital and emergency room settings and has dramatically increased the diagnostic productivity of physicians, he said. In the ER, CT has replaced the physical exam to speed patient triage.

In contrast to Brenner and Hall's public health concerns about CT, Dr. Brant-Zawadzki stressed its contributions.

"It has saved countless thousands of lives," he said.

Articles in this issue

Third-line single-agent cetuximab ups overall survival
Modern multislice CT propels pancreas imaging forward
Sorafenib gets ok for liver cancer
Celgene to acquire Pharmion
Novacea halts ASCENT-2 trial
RT/temozolomide raises possibility of cure in glioblastoma
Brachytherapy as effective in younger as in older men
MMA not harming patients
Kinase inhibitor may prevent RT-induced lung injury
FDA approves lower starting dose for dasatinib for CML
Encouraging Avastin results in glioblastoma multiforme
Sunitinib is cost-effective in metastatic renal ca patients
The role of imaging in microsphere therapy of liver mets
Free website offers chemo order forms
MR tops x-ray and scintigraphy for detecting bone mets
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content
Advertisement

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

Roman Fabbricatore
September 12th 2025
Article

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 12th 2025
Article

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.


Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.

Related Content
Advertisement

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

Roman Fabbricatore
September 12th 2025
Article

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 12th 2025
Article

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.


Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.